K D Tutsch

1.6k total citations
22 papers, 1.4k citations indexed

About

K D Tutsch is a scholar working on Oncology, Molecular Biology and Biochemistry. According to data from OpenAlex, K D Tutsch has authored 22 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Biochemistry. Recurrent topics in K D Tutsch's work include Cancer Treatment and Pharmacology (8 papers), Amino Acid Enzymes and Metabolism (4 papers) and HER2/EGFR in Cancer Research (4 papers). K D Tutsch is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Amino Acid Enzymes and Metabolism (4 papers) and HER2/EGFR in Cancer Research (4 papers). K D Tutsch collaborates with scholars based in United States, Netherlands and Spain. K D Tutsch's co-authors include Dona Alberti, R Z Arzoomanian, D L Trump, Chris Feierabend, Marcia Pomplun, David R. Spriggs, George Wilding, James K. V. Willson, Ajit Kumar Verma and Howard H. Bailey and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Chemotherapy and Pharmacology.

In The Last Decade

K D Tutsch

22 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K D Tutsch United States 17 544 492 207 183 170 22 1.4k
Kendra D. Tutsch United States 19 502 0.9× 773 1.6× 175 0.8× 207 1.1× 98 0.6× 39 1.5k
D. Lee Gorden United States 24 538 1.0× 623 1.3× 177 0.9× 300 1.6× 197 1.2× 38 1.9k
Wolfram C. M. Dempke Germany 20 727 1.3× 727 1.5× 217 1.0× 258 1.4× 154 0.9× 48 1.8k
Susanne Gansauge Germany 24 807 1.5× 826 1.7× 84 0.4× 281 1.5× 87 0.5× 53 1.8k
E.L. Levine United Kingdom 11 481 0.9× 351 0.7× 445 2.1× 290 1.6× 386 2.3× 17 1.4k
Raffaele Longo Italy 19 571 1.0× 567 1.2× 194 0.9× 326 1.8× 120 0.7× 64 1.5k
Tonya C. Walser United States 23 840 1.5× 846 1.7× 164 0.8× 423 2.3× 135 0.8× 41 2.1k
Thomas W. Davis United States 24 634 1.2× 1.1k 2.3× 301 1.5× 457 2.5× 189 1.1× 54 2.0k
Denise K. Oelschlager United States 20 325 0.6× 602 1.2× 92 0.4× 197 1.1× 155 0.9× 41 1.2k
C. Rancoule France 22 312 0.6× 687 1.4× 166 0.8× 198 1.1× 44 0.3× 77 1.7k

Countries citing papers authored by K D Tutsch

Since Specialization
Citations

This map shows the geographic impact of K D Tutsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K D Tutsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K D Tutsch more than expected).

Fields of papers citing papers by K D Tutsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K D Tutsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K D Tutsch. The network helps show where K D Tutsch may publish in the future.

Co-authorship network of co-authors of K D Tutsch

This figure shows the co-authorship network connecting the top 25 collaborators of K D Tutsch. A scholar is included among the top collaborators of K D Tutsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K D Tutsch. K D Tutsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilding, George, K D Tutsch, R Z Arzoomanian, et al.. (2004). A phase I trial of perillyl alcohol administered four times daily for 14�days out of 28�days. Cancer Chemotherapy and Pharmacology. 54(4). 25 indexed citations
2.
Messing, Edward M., Richard R. Love, K D Tutsch, et al.. (1999). Low-Dose Difluoromethylornithine and Polyamine Levels in Human Prostate Tissue. JNCI Journal of the National Cancer Institute. 91(16). 1416–1417. 15 indexed citations
3.
Berlin, Jordan, Barry E. Storer, K D Tutsch, et al.. (1998). Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.. Journal of Clinical Oncology. 16(3). 1142–1149. 5 indexed citations
4.
Rietbroek, Ron C., Dörthe M. Katschinski, Monique H. Reijers, et al.. (1997). Lack of thermal enhancement for taxanesin vitro. International Journal of Hyperthermia. 13(5). 525–533. 36 indexed citations
5.
Bailey, Howard H., Gregory H. Ripple, K D Tutsch, et al.. (1997). Phase I Study of Continuous-Infusion L-S,R-Buthionine Sulfoximine With Intravenous Melphalan. JNCI Journal of the National Cancer Institute. 89(23). 1789–1796. 139 indexed citations
6.
Berlin, Jordan, K D Tutsch, Paul R. Hutson, et al.. (1997). Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.. Journal of Clinical Oncology. 15(2). 781–789. 44 indexed citations
7.
Robins, H. Ian, Daniel A. Rushing, K D Tutsch, et al.. (1997). Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.. Journal of Clinical Oncology. 15(1). 158–164. 74 indexed citations
8.
McGinn, C.J., Keith A. Kunugi, K D Tutsch, et al.. (1996). Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.. PubMed. 2(8). 1299–305. 6 indexed citations
9.
Bailey, Howard H., Ríona Mulcahy, K D Tutsch, et al.. (1994). Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.. Journal of Clinical Oncology. 12(1). 194–205. 161 indexed citations
10.
Schiller, Joan H., B. Storer, K D Tutsch, et al.. (1994). Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.. Journal of Clinical Oncology. 12(2). 241–248. 111 indexed citations
11.
Schiller, Joan H., Barry E. Storer, K D Tutsch, et al.. (1994). A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.. PubMed. 21(5 Suppl 8). 9–14. 16 indexed citations
12.
Chan, Kenneth K., et al.. (1994). Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.. PubMed. 54(24). 6421–9. 38 indexed citations
13.
Love, Richard R., Paul P. Carbone, Ajit Kumar Verma, et al.. (1993). Randomized Phase I Chemoprevention Dose-Seeking Study of  -Difluoromethylornithine. JNCI Journal of the National Cancer Institute. 85(9). 732–737. 75 indexed citations
14.
Robins, H. Ian, Justin Cohen, Carol L. Schmitt, et al.. (1993). Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.. Journal of Clinical Oncology. 11(9). 1787–1794. 46 indexed citations
15.
Bailey, Howard H., et al.. (1991). Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.. PubMed. 51(4). 1105–8. 9 indexed citations
16.
Trump, D L, Merrill J. Egorin, Alan Forrest, et al.. (1991). Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.. Journal of Clinical Oncology. 9(11). 2027–2035. 73 indexed citations
17.
Willson, James K. V., Paul H. Fischer, Scot C. Remick, et al.. (1989). Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.. PubMed. 49(7). 1866–70. 33 indexed citations
18.
Fischer, Paul H., et al.. (1988). Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion.. PubMed. 48(19). 5591–6. 13 indexed citations
19.
Grem, Jean L., K D Tutsch, Dona Alberti, et al.. (1987). Phase I study of taxol administered as a short i.v. infusion daily for 5 days.. PubMed. 71(12). 1179–84. 92 indexed citations
20.
Earhart, Robert H., K D Tutsch, Jim M. Koeller, et al.. (1982). Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients.. PubMed. 42(12). 5255–61. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026